BioInvent International AB (publ)

OM:BINV Stock Report

Market Cap: SEK 2.7b

BioInvent International Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BINV?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders549,2330.835%
Hedge Funds10,127,86015.4%
Institutions11,611,81417.6%
General Public21,203,49432.2%
VC/PE Firms22,311,96133.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 67.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.4%
Redmile Group, LLC
10,127,860SEK 420.3m0%2.05%
10.1%
Van Herk Investments B.V.
6,630,965SEK 275.2m0%2.14%
9.81%
Forbion Capital Partners B.V.
6,457,785SEK 268.0m0%3.87%
7.71%
HBM Partners Ltd.
5,075,000SEK 210.6m0%1.85%
6.3%
Omega Fund Management, LLC
4,148,211SEK 172.2m0%7.78%
6.11%
Fourth Swedish National Pension Fund (AP4)
4,023,281SEK 167.0m0%0.06%
3.42%
Goldman Sachs Group, Investment Banking and Securities Investments
2,251,288SEK 93.4m0%no data
3.13%
Avanza Fonder AB
2,057,163SEK 85.4m0%0.09%
2.52%
Handelsbanken Asset Management
1,657,311SEK 68.8m0%0.01%
0.68%
Rhenman & Partners Asset Management AB
450,000SEK 18.7m0%0.11%
0.54%
SEB Investment Management AB
352,468SEK 14.6m2.39%no data
0.51%
Skandia Fonder AB
333,832SEK 13.9m0%0.01%
0.46%
Dharminder Chahal
300,000SEK 12.5m0%no data
0.35%
FCG Fonder AB
231,329SEK 9.6m0%0.1%
0.16%
Dimensional Fund Advisors LP
104,992SEK 4.4m6.46%no data
0.14%
Medical Strategy GmbH, Asset Management Arm
94,000SEK 3.9m0%0.02%
0.1%
Bernd Seizinger
66,000SEK 2.7m0%no data
0.076%
Storebrand Fonder AB,
49,781SEK 2.1m0%no data
0.051%
Leonard Kruimer
33,538SEK 1.4m0%no data
0.044%
Kristoffer Bissessar
29,000SEK 1.2m0%no data
0.035%
Björn Frendéus
23,089SEK 958.3k0%no data
0.035%
Sylvie Ryckebusch
22,870SEK 949.0k0%no data
0.034%
Martin Welschof
22,400SEK 929.6k0%no data
0.034%
Kristoffer Hansson
22,303SEK 925.5k0%no data
0.027%
Erik Esveld
18,000SEK 746.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 03:53
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Camilla OxhamreCarnegie Investment Bank AB
Mattias HäggblomDanske Bank